|
Baseline biomarkers correlated with outcome in advanced melanoma treated with pembrolizumab monotherapy. |
|
|
Employment - Abbott Laboratories (I) |
Consulting or Advisory Role - Novartis |
Research Funding - Novartis (Inst); Pfizer (Inst) |
Travel, Accommodations, Expenses - Astellas Pharma; MSD Oncology; Novartis; Pfizer |
|
|
Travel, Accommodations, Expenses - Amgen; MSD |
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Pfizer |
|
|
Employment - NanoString Technologies |
Travel, Accommodations, Expenses - NanoString Technologies |
|
|
Employment - NanoString Technologies |
|
|
Employment - NanoString Technologies |
Stock and Other Ownership Interests - NanoString Technologies |
Consulting or Advisory Role - Petra Pharma |
|
|
No Relationships to Disclose |
|
|
Employment - Johnson & Johnson (I) |
Consulting or Advisory Role - Novartis |
Speakers' Bureau - Novartis |
Travel, Accommodations, Expenses - GlaxoSmithKline; MSD; Novartis |
|
|
Research Funding - Camel-IDS (Inst) |
Patents, Royalties, Other Intellectual Property - Vrije Universiteit Brussel (Inst) |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pfizer/EMD Serono; Roche; Sanofi |
Speakers' Bureau - Novartis |
Research Funding - Merck KGaA (Inst); Novartis (Inst); Pfizer (Inst) |
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche |